Strategic R&D Roadmap

Four-phase product pipeline strategy driving innovation across Africa

Phase 1

Technology Barrier

Focus: High-demand biologics & Vaccines

Key Assets:

司美格鲁肽 (Semaglutide)替尔泊肽 (Tirzepatide)依柯胰岛素 (Icodec Insulin)非奈利酮 (Finerenone)HPV和PCV疫苗
Phase 2

Innovative Biologics

Focus: Next-gen therapies with higher accessibility

Key Assets:

口服司美格鲁肽贝伐珠单抗 (Bevacizumab)利妥昔单抗 (Rituximab)曲妥珠单抗 (Trastuzumab)阿达木单抗 (Adalimumab)
Phase 3

Collaborative R&D

Focus: Shared risk, accelerated tech transfer

Key Assets:

PD-1来那卡帕韦 (Lenacapavir)口服PCSK9依柯胰岛素和GLP-1复合剂 (IcoSema)
Phase 4

Frontier Research

Focus: Breakthrough platforms

Key Assets:

超长效GLP-1RetatrutideMalaria Vaccine (疟疾疫苗)

Leveraging Advanced Platforms

Leveraging the power of the mRNA and Peptide platforms, we are addressing Africa's most pressing health challenges: from Diabetes to Infectious Diseases.